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A B S T R A C T
The improvement in supportive care and the introduction of new therapeutic agents, including lenalidomide and
hypomethylating agents, in myelodysplastic syndromes have improved patients’ outcomes; however, at the same
time, the frequency and epidemiology of infections have changed. Therefore, the great strides in the indications
and use of new treatment strategies for myelodysplastic syndromes need a parallel progress in the best approach
to prophylaxis and supportive therapy for infections. Based on the recognition that the above issues represent an
unmet clinical need in myelodysplastic syndromes, an Italian expert panel performed a review of the literature
and composed a framework of the best recommendations for optimal infection control in patient candidates to
receive active treatment for myelodysplastic syndromes. In this consensus document we report the outcomes of
that review and of the consensus meetings held during 2017. The issues tackled in the project dealt with:
information to be collected from candidates for active treatment for myelodysplastic syndromes; how to monitor
the risk of infection; antimicrobial prophylaxis; the role of iron chelation and antiviral/antibacterial vaccina-
tions. For each of these issues, practice recommendations are provided.
1. Introduction
Myelodysplastic syndromes (MDS) are a group of clonal myeloid
malignancies with variable clinical presentation and disease prognosis.
In lower-risk MDS, erythropoiesis-stimulating agents and lenalidomide
are the recommended treatments, whereas hypomethylating agents
(HMAs) are considered the standard of care in higher-risk MDS patients
for whom allogeneic stem cell transplant is not feasible [1–3]. Out of
the HMAs azacitidine, decitabine and, very recently, guanecitabine
actually azacitidine is the most widely used in higher-risk MDS patients.
Infections historically represent a major complication in MDS patients;
however, their frequency and spectrum in the different subgroups of
MDS patients receiving current treatment approaches has not been
specifically investigated and infection-control strategies, in particular
anti-infective prevention for high-risk disease, have not been standar-
dized [4–7]. Hence, the great strides in the treatment of MDS patients
need parallel progress in the best approach to prophylaxis and sup-
portive treatment for infections.
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Based on these considerations, a panel of Italian experts in the
management of MDS patients took part in a project aimed at providing
useful recommendations for the risk stratification and prevention of
infectious complications in MDS patient candidates for active treat-
ment.
2. Methods
The expert panel included 12 hematologists selected because of
their expertise in research and clinical practice of MDS. An Advisory
Committee chaired by four clinicians (CG, RL, MTV, VS) with expertise
in clinical epidemiology ensured the proper methodology of the pro-
cess. The goal of the project was to develop recommendations for in-
fection-control strategies in patients with MDS who were candidates for
active treatment other than acute myeloid leukemia (AML)-like che-
motherapy and allogeneic hematopoietic stem cell transplant. The areas
of major concern in the infection-control strategy in MDS patients were
selected by generating clinical key questions using the criterion of
clinical relevance, i.e., impact on the management of patients and risk
of inappropriateness, through a Delphi process [8]. The Delphi method
is a structured, interactive communication technique which relies on a
panel of experts The experts answer questionnaires in two or more
rounds. After each round, a facilitator provides a summary of the ex-
perts' forecasts from the previous round as well as the reasons they
provided for their judgments. Thus, experts are encouraged to revise
their earlier answers in light of the replies of other members of their
panel. It is believed that during this process the range of the answers
will decrease and the group will converge towards the "correct" answer.
The Advisory Committee examined the current state of knowledge re-
garding infection-control strategies in patient candidates for active
treatment of MDS, identified key questions and drafted statements to
address these questions. A systematic review of the literature on the
epidemiology of infections in MDS populations was performed using the
PubMed database, limiting the choice to English-language articles. Ar-
ticles that included large single center or multicenter series of MDS
patients, as well as review articles and position papers by other expert
groups, were considered. During the first meeting in February 2017, the
key questions proposed by the Advisory Committee were discussed and
approved by the expert panel, and one or more panelists were given the
task of producing recommendations for a specific key question based on
literature analysis and their own experience. Each panelist scored their
agreement with the statements made by the other panelists and pro-
vided suggestions for rephrasing. The ensuing comments were centrally
combined for a subsequent round of electronic consultation; agreement
on the statements and approval of the full body of recommendations
were definitively reached during a second meeting in December 2017.
The overall goal of the meetings was to reach a definite consensus over
question-specific statements for which there was disagreement during
the first-round postal phase. We used the nominal group technique [9] –
a group process involving problem identification, solution generation,
and decision making - through which participants were first asked to
comment in round-robin fashion on their preliminary votes and then to
propose a new vote. First, every member of the group gave their view of
the solution, with a short explanation. Then, duplicate solutions were
eliminated from the list of all solutions, and the members proceeded to
rank the solutions, 1st, 2nd, 3rd, 4th, and so on. If an 80% consensus on
the statement was not achieved, the choices were discussed and a fur-
ther vote taken. If an 80% consensus was still not attained, the issue was
declared unresolved and no further attempt was made. A facilitator
(CG) encouraged the sharing and discussion of reasons for the choices
made by each group member, thereby identifying common ground, and
a plurality of ideas and approaches. Recommendations specifically
considered the current MDS treatment strategies, which require proper
stratification according to the International Prognostic Scoring System
(IPSS) or the IPSS-Revised (IPSS-R) [2,3].
3. Epidemiology of infections in patients with MDS receiving
current therapy
In patients with MDS, infectious complications have a highly vari-
able incidence according to MDS subtype, patient characteristics and
treatment [4,5].
Considering the MDS intrinsic immune impairment, several patients
have an infection at the onset of the disease before starting any treat-
ment. Although the observation of an infection in MDS patients at the
onset of the disease is common in the clinical practice, specific pro-
spective epidemiological studies are scarce in this phase and most of the
recent data in MDS populations are derived from retrospective studies
in patients at different phases of the disease or from Phase II–III clinical
trials performed to test new therapeutic agents for MDS; therefore,
endpoints are different from incidence of infectious complications.
Moreover, to date, the infectious risk in MDS and the real impact of
these complications on the survival of MDS patients are still unclear
[4]. In a recent report from the Dusseldorf registry, examining cause of
death in a large cohort of 3792 patients with MDS, 2877 patients (75.9
%) had deceased at the time of analysis. From 1665 patients with a
clearly documented cause of death, 449 (27%) died as a result of an
infection [10].
Table 1 shows the most recent prospective Phase II and III clinical
trials testing new drugs in MDS and reporting information on infectious
adverse events [11–21]. Table 2 shows the results of retrospective ob-
servational studies focused on infectious complications in MDS patients
[5,7,22–26]. As detailed, infectious complications have a variable, but
not negligible, incidence, especially in clinical trials enrolling higher-
risk MDS patients (including IPSS-R intermediate to very high), in
which the rate of grade ≥3 infections reaches 58% of treated cases
[13]. Conversely, in studies involving lower-risk MDS patients, infec-
tions and febrile neutropenia of grade ≥3 are less frequent, ranging
from 2% to 21% of treated cases [5,17–19].
The effect of HMA therapy in worsening cytopenia and in increasing
the risk of infection in MDS is still poorly documented. In fact, in early
studies in patients with higher- and lower-risk MDS (CALBG 8421,
8921, 9221 trials) receiving azacitidine, there was no increase in the
infection rate during azacitidine therapy compared with the “best
supportive care” cohort [27]. However, more recent “real-world” stu-
dies have suggested an increase in infectious events in higher-risk MDS
patients treated with HMAs, especially during the early (first 2–3) cy-
cles of therapy, before achieving a response, when the drug-induced
cytopenia is associated with active-phase MDS [4,25,26]. In addition,
clinical trials clearly show that the percentage of infectious events is
high, not only in the therapeutic arm but also in the control group,
emphasizing that there is an inherent risk of infection in MDS, re-
gardless of the therapeutic approach, due to both neutropenia and the
altered function of neutrophils [11–14,19–21]. When detailed, most
reported infections in MDS occur in the presence of neutropenia and are
prevalently of bacterial origin, with subsequent pneumonia, bacteremia
and/or sepsis [4,28,29].
4. Infectious risk assessment and monitoring
4.1. Which MDS patients eligible for active treatment are at higher risk of
infection, and what information and tests are recommended to identify/
stratify the risk of infection?
4.1.1. Preliminary considerations
Although infections may occur and cause death independently of
specific risk factors [10,28–35], baseline neutropenia, present
in> 50% of higher-risk IPSS/IPSS-R and 15–20% of lower-risk MDS, is
likely the main predisposing factor in these patients [4,6,29,35]. Fur-
thermore, several other functional defects of granulocytes, as well as
various types of B-, T-, natural killer and regulatory T-cell abnormal-
ities, have been reported to also impair the response to infectious
C. Girmenia et al. Blood Reviews 34 (2019) 16–25
17
microorganisms in the absence of neutropenia in patients with MDS
[4,31]. The true contribution of such abnormalities to the development
of infections in MDS, however, has not been specifically investigated in
the clinical setting.
Frailty, chronic infections or previous severe infectious episodes,
environmental (home, hospital), and patients’ (airways) bacterial or
fungal colonizations, iron overload (IO), bone marrow reserve (cyto-
penias) and biological status of the disease (number of blasts and ge-
netic characteristics), have all been variably associated with an in-
creased risk of infections and with their severity [4–6,29,34,36–38].
Importantly, specific drugs and treatments currently employed in
MDS, which have demonstrated efficacy in selected subtypes, can also
transiently worsen or determine severe neutropenia and im-
munosuppression, thus possibly playing an additional relevant role in
the development of infections. In this setting, no evidence of an in-
creased risk of infection (in particular life-threatening pneumonia and
sepsis) has been reported in two prospective, randomized trials com-
paring azacitidine to best supportive care [11,27]. However, azacitidine
induced sustained neutropenia (grade 3–4) in up to 91% of these pa-
tients, including those who had baseline grade 0–2 and shifted to grade
3–4 neutropenia on therapy (84%). Of interest, the infection rate in
azacitidine-treated patients was significantly lower than in those re-
ceiving low-dose cytarabine or intensive chemotherapy, resulting in a
34% reduction in the rate of infection [11].
In a retrospective study of 184 patients treated with azacitidine, the
most relevant prognostic factors for infections in a multivariate analysis
were low platelet counts (< 20×10 [9]/L), poor risk cytogenetics and
low hemoglobin levels (< 10 g/dL) [26]. In this study, absolute neu-
trophil counts before each azacitidine cycle and marrow blast percen-
tage (but not age, transfusion dependency, azacitidine dose or serum
creatinine) were also found to be risk factors in the univariate analysis,
but they did not maintain their prognostic relevance in the multivariate
model. Two studies reported a higher risk of infectious complications in
patients treated with azacitidine 75 mg/m2 for 7 days, than in those
receiving 5 days of therapy either in the first cycle [39] or during the
entire treatment [40]. Notably, the rate of infectious events tended to
decline with sequential azacitidine cycles (in particular after the first
three cycles) [7,23,25,26,41,42]. This is probably due to the pro-
gressive resolution of neutropenia in responders.
In another retrospective study, febrile episodes appeared to be more
frequent if intensive chemotherapy had been employed before azaciti-
dine, compared with when azacitidine was used frontline [25]. In this
study, there was no relationship between neutrophil counts lower than
0.5×10 [9]/L and probability of infectious complications; however,
severe neutropenia was associated with a higher incidence of proven/
probable invasive fungal diseases (IFDs) in MDS patients receiving
azacitidine [24].
Response to azacitidine impacts on the probability of infections,
with a significantly lower prevalence of these complications in patients
who achieved at least a hematologic response, compared with those
with progressive or stable disease [23]. In this study, older age was
associated with a not significant higher rate of infections, whereas co-
morbidities or IPSS-R had no influence. Conversely, a very high IPSS-R
has recently been identified as an independent risk factor for infections
in azacitidine-treated patients, with a relevant attributable mortality
[7].
In another real-world Italian experience in 184 MDS patients treated
with azacitidine, higher platelet levels were the only factor associated
with an increased incidence of febrile events, whereas age, months from
diagnosis, hemoglobin, white blood cell and neutrophil counts, bone
marrow blasts, MDS comorbidity index, body mass index, IPSS and
IPSS-R, azacitidine dose, and response were not [41]. Of note, at the
time of the events, disease remission had not been achieved in most
cases (only 11% of events occurred in responsive patients); a high risk
of death due to pneumonia and bowel infection was also observed. An
infectious event was the attributable cause of death mainly in patientsTa
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with progressive or stable disease.
IFDs have been reported at rates varying between 4% and 12% in
MDS patients undergoing HMA therapy [26,39,43,44]. The rate was
significantly higher in those who had received previous intensive che-
motherapy, up to about 25% [25]. Similar to other infections, the risk
of IFD was highest during the first three treatment cycles.
Pulmonary infections are associated with poor prognosis in MDS
patients treated with azacitidine [41,44]. Given the different etiologies,
interstitial pneumonia associated with azacitidine should be differ-
entiated from other lung infections [45].
Specific data on the risk of infections associated with decitabine
treatment in MDS are limited. Overall, decitabine appears to increase
myelotoxicity compared with azacitidine. In particular, one compara-
tive, retrospective study found that patients who had received decita-
bine experienced more frequent episodes of grade 3 or 4 cytopenia and
infection than those receiving azacitidine; this was particularly frequent
in elderly patients [43]. In a retrospective study of 85 AML and MDS
patients treated in a prospective clinical study using 10-day cycles of
decitabine, culture results were available for 163 infection-related
complications that occurred in 70 patients. Infection-related deaths
occurred only in Gram-negative events (13%); infection-related com-
plications occurred during any cycle of therapy, and the incidence did
not decrease during later cycles [22]. A recent meta-analysis has in-
dicated that the rate of infections in decitabine-treated patients did not
decrease when reducing the decitabine dose [46].
In prospective and retrospective, real-life studies, lenalidomide in-
duced grade 3–4 neutropenia in most (about three-quarters) of treated
patients (55% in a Phase II study), mainly during the first 8 weeks of
treatment [17,18,47]. As a consequence, infections were frequently
observed in these patients, although<15% were of a higher grade
(febrile neutropenia 1–3%). Similar results have been reported in
higher-risk patients with complex karyotypes including del5q [48],
whereas in lower-risk MDS without del5q, severe neutropenia and in-
fections seem to be less frequent [49]. Development of neutropenia is
significantly associated with treatment response only in del5q MDS,
suggesting specificity of the cytotoxic action of lenalidomide [15].
Septic deaths associated with neutropenia in lenalidomide-treated MDS
patients have been reported, particularly in patients who present with
worsening neutropenia under treatment [47]. Interestingly, del5q has
been recently associated with interstitial lung disease, the etiology of
which may include recurrent infections [50].
The risk of infections in advanced MDS receiving intensive che-
motherapy may not be different from that of AML patients of similar
age, treated with the same regimens and experiencing comparable
duration of neutropenia, although this is not supported by dedicated
studies. For these patients, hospitalization and use of central venous
catheters might represent additional risk factors [36].
Overall, immunosuppressive therapies have been associated with an
increased risk of infection in MDS [34], although the specific role of
antithymocyte globulin and/or cyclosporine has not been clearly re-
ported in patients eligible for these treatments (i.e., with hypoplastic
MDS) [51].
Recommendations for infectious risk management should be gen-
erally tailored on the basis of treatment aims, although a well-defined
infection risk-based algorithm aiming at selecting specific treatments
for specific patients has not yet been developed. This is mainly due to:
(i) the inconsistency/heterogeneity of data so far reported in the lit-
erature; (ii) the currently still limited therapeutic armamentarium of
MDS, which has well-established targets that do not allow significant
alternative options in the therapeutic approach based on infectious risk.
The association of the patient and disease variables with the risk of
infections according to the above studies has been summarized in
Table 3. The results of the various studies were conflicting so it was not
possible to elaborate recommendations as the result of a meta-analysis
of available data but rather as an expert opinion based both on the
personal experience and the subjective interpretation of the literature
data.
4.1.2. Recommendations
The panel considered the following conditions at higher risk of in-
fection, requiring careful evaluation and monitoring:
• Patients with baseline severe and prolonged cytopenia (ANC<500/
cmm for more than 1 month) and Iron Overload secondary to
packed red blood cell transfusions (sees next paragraph on iron
overload).
• Presence of single or combined relevant comorbidities (chronic
liver, heart and renal organ failures, chronic obstructive pulmonary
diseases, diabetes, other malignancies and autoimmune disorders).
• Chronic infections and previous severe infectious episodes (i.e. in-
fections which required hospitalization and/or parenteral anti-
microbial therapy).
• Recent hospitalization.
The following anamnestic, clinical, laboratory, instrumental and
environmental data were considered useful in this setting:
• Accurate personal and medical history and concomitant medications
(particularly steroids and other agents inducing cytopenia and/or
immunosuppression), secondary MDS, duration of MDS.
• Environmental and occupational exposure as significant risk factors
for IFD.
• Baseline laboratory assessments, including depth and duration of
neutropenia, the presence of Iron Overload, immunoglobulin levels
and viral profiles (particularly hepatitis B virus [HBV] and hepatitis
C virus [HCV]).
• Instrumental work-up: chest X-ray or computed tomography, parti-
cularly in patients with prior pulmonary infections. Although chest
X-ray is a radiological method that is easy to perform and represents
a standard in the diagnosis of pulmonary infections, especially in the
outpatient setting, computed tomography could be preferred as a
more sensitive and specific method, especially in neutropenic pa-
tients.
• Local infectious epidemiology in hospitalized patients.
4.2. What schedule of clinical and laboratory assessments and follow-up
management should be applied (outside of acute infectious episodes) to
evaluate the risk of infection in patients with MDS?
4.2.1. Preliminary considerations
There are no specific guidelines on the pre-treatment and on-treat-
ment infectious screening in MDS patients. Therefore, the re-
commendations on clinical and laboratory parameters that should be
considered in order to predict the infectious risk in these patients
generally derive from those used in other cancer and high-risk popu-
lations. We shall focus our recommendations on the pre-treatment
screening and management of HBV infection, HCV infection, tubercu-
losis (TB), multidrug-resistant (MDR) bacteria and fungi [52–55].
Reactivation of HBV infection in hematologic patients undergoing
immunosuppressive or antineoplastic treatment occurs in approxi-
mately 20–50% of surface antigen of HBV (HBsAg)-positive (chronic
HBV infection) patients and< 1–10% in HBsAg-negative/hepatitis B
core antibody (anti-HBc)-positive (resolved HBV infection) patients.
However, most of the literature refers to patients with lymphoproli-
ferative diseases or acute leukemia, whereas there is no information
pertaining to the incidence of HBV infection and the risk of HBV re-
activation in patients with MDS. In particular, clinical trials in patients
treated with lenalidomide or HMAs did not report HBV reactivations as
adverse events [7,11–21,29]. Consequently, recommendations given
for other low-risk populations may be used as reference [52,53]. It
should also be considered that the evolving nature of MDS and sub-
sequent treatments may change the antiviral strategy over time in each
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patient. In all patients about to receive treatment for a malignant dis-
ease, HBV screening is recommended for planning a prophylaxis
strategy or the laboratory monitoring of seroreversion and/or viremic
rebound, and the subsequent introduction of pre-emptive therapy
[52,53].
Increases in liver enzyme activity are common in HCV RNA-positive
patients receiving chemotherapy, but such increases are usually mild to
moderate. Some studies have suggested that chemotherapy does not
increase the risk of clinically significant hepatotoxicity in HCV RNA-
positive patients with hematologic malignancies [52].
Targeted screening and treatment of latent TB infection (LTBI) is an
important strategy for groups at high risk of developing active TB. A
recent meta-analysis showed that patients with hematologic cancer
have a nine-fold higher rate of developing active TB compared with
those without cancer and would benefit from targeted latent TB
screening and therapy [55]. However, no data are specifically available
for patients with MDS.
During the outpatient management of MDS patients, colonization by
MDR Gram-negative bacteria and subsequent infection are uncommon.
Conversely, in patients with severe neutropenia, infections by MDR
bacteria may be significant, particularly in hospitals with high pre-
valence of such pathogens. In these cases, knowledge of colonization
patterns may be required to define infection-control measures and tai-
lored antibiotic therapy [56,57]. Actually infections and colonization
by MDR gram positive bacteria [i.e. methicillin resistant Staphylo-
coccus aureus (MRSA) and vancomycin resistant Enterococci (VRE)] do
not seem to represent challenging problems in hematologic patients.
The role of fungal colonization and antigen monitoring in the
overall management of IFDs in patients with hematologic malignancies
is a debated issue. It could be taken into consideration in high-risk
conditions, but it does not seem to be cost-effective in populations at
moderate to low risk of IFDs, such as those affected by MDS.
4.2.2. Recommendations
The following HBV and HCV screening is recommended in all pa-
tients at the diagnosis of MDS:
• HBV and HCV
o HBsAg, anti-HBc, anti-HBsAg, HBV DNA if HBsAg or anti-HBc
detected, anti-HCV and HCV RNA if anti-HCV-positive.
• Tuberculosis
o We recommend screening with interferon-γ-release assays
(IGRAs) or tuberculin skin testing (TST) or combined TST-IGRA
testing to detect LTBI in all patients regardless of the MDS treat-
ment strategy in high TB prevalence regions [58].
o In low TB prevalence regions [58], screening is recommended in
patients with a suspected history of TB infection, in those who
come from high TB prevalence regions and in those who have
other conditions that are associated with an increased risk of TB
infection.
• MDR bacteria
o We do not recommend monitoring colonization by MDR bacteria
during outpatient management.
o Conversely, in hospitalized patients colonization screening with
rectal swab culture is recommended to detect colonization by
MDR Gram-negative bacteria in hospitals with high prevalence.
When a patient with colonization or infection by such micro-
organism is detected, all patients in the ward should be monitored
regardless of the underlying disease or condition. Colonization
screening should be performed at hospital admission and weekly
if other cases of colonization or infection are present in the ward.
o Patients colonized by certain MDR Gram-negative bacteria (i.e.,
carbapenem-resistant enterobacteria, MDR Pseudomonas aerugi-
nosa) may require precautions for contact infections and tailored
antibiotic therapy in the event of febrile neutropenia or deep in-
fections.
• Fungi
o Surveillance cultures for colonization by fungi (either yeasts or
molds) are not recommended in any MDS treatment phase.
o Surveillance screening of fungal antigens (galactomannan, beta-D-
glucan) is not recommended.
Table 3
Risk factors of infectious complications in MDS patients: summary of available literature data.
Risk factors Comments
Age In most of studies there was no clear association between age and infectious risk [23,26,41].
Comorbidities Comorbidities had variable and no clear influence in the rate of infections [23,41].
Neutrophil count Absolute neutrophil counts before each azacitidine cycle were found to be risk factors in the univariate
analysis [26]. In another study there was no relationship between neutrophil counts lower than 0.5×109/L
and probability of infectious complications [25]. Severe neutropenia was associated with a higher incidence
of proven/probable invasive fungal diseases (IFDs) in MDS patients receiving azacitidine [24].
Hemoglobin levels Low hemoglobin levels (< 10 g/dL) was predictive of the risk of infection during the first two cycles of
therapy at multivariate analysis [26]. This correlation was not observed in another study [41].
Platelet counts Low platelet counts (< 20×109/L) was predictive of the risk of infection during the first two cycles of
azacitidine therapy at multivariate analysis in a study [26], conversely in another real-world experience in
MDS patients treated with azacitidine, higher platelet level was the only factor associated with an increased
incidence of febrile events [41].
Blast percentage, cytogenetic risk and International Prognostic
Scoring System Revised (IPSS-R)
Marrow blast percentage before each azacitidine cycle was found to be risk factor in the univariate analysis,
but not in the multivariate model [26]. Poor cytogenetics was predictive of the risk of infection during the
first two cycles of therapy at multivariate analysis [26]. A very high IPSS-R has been identified as an
independent risk factor for infections in azacitidine-treated patients, with a relevant attributable mortality, in
a study [4], while IPSS or IPSS-R had no influence in the rate of infections in another experience [23].
Hypomethylating agents treatment Response: response to azacitidine impacted on the probability of infections in one study [23], while no
correlation was observed in another experience [41].
Dosage: a higher risk of infectious complications was observed in patients treated with azacitidine 75 mg/m2
for 7 days, than in those receiving 5 days of therapy [39,40]. This association was not observed in other
experiences [23,26] The rate of infections in decitabine-treated patients did not decrease when reducing the
decitabine dose [46].
Cycles: the rate of infectious events was higher in the first 3 azacitidine cycles and tended to decline with
sequential cycles [7,23,25,26,41,42].
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5. Prevention of infections
5.1. In which MDS patients and when is prophylaxis with antibacterial and/
or antifungal and/or antiviral drugs recommended according to treatment?
5.1.1. Preliminary considerations
There are no data on antimicrobial prophylaxis specifically in MDS
populations with the exception of those treated with AML-like che-
motherapy or allogeneic stem cell transplant. In particular, to our
knowledge, no study of antibacterial, antifungal or antiviral prophy-
laxis has been published to date. For these reasons, recent guidelines
and experts do not recommend the use of primary antibacterial, anti-
fungal or antiviral prophylaxis, nor the use of granulocyte-colony sti-
mulating factor (G-CSF) in MDS patients receiving active treatment,
including HMAs [3,4,41,59,60].
Recent studies focusing the infection risk in patients receiving HMA
treatments showed an increased infectious risk during the first 2-3 cy-
cles before achieving a response, when the drug-induced cytopenia is
associated with active-phase MDS [4,7,25,26]. Although no experience
in the use of any antimicrobial prophylaxis has been reported in this
specific setting to our knowledge, a primary antibacterial and anti-
fungal prohylaxis limited to this early period may be hypothesized, also
considering that the early interruption of the HMA treatment due to a
complication may negatively impact on the overall outcome of the
disease.
Secondary antibacterial, antifungal and anti-herpetic prophylaxis
and the use of G-CSF have been suggested in patients with a history of
severe infections.
An important issue when certain drugs are coadministered is re-
presented by the possible pharmacokinetic drug-drug interaction.
Considering that HMAs and lenalidomide are not a substrate of human
CYP450 enzymes and are not subjected to direct conjugative metabo-
lism there is no drug–drug interaction when coadministered with CYP
and P-gp inhibitors, inducers, or substrates. Consequently, no precau-
tion is required when any antibacterial, antifungal and antiviral drugs
are administered concomitantly with HMAs and lenalidomide.
5.1.2. Recommendations
• Primary antibacterial, antifungal and anti-herpetic prophylaxis is
generally not recommended.
• In patients at higher risk of infection (in particular those with
chronic obstructive pulmonary diseases, recent antibacterial treat-
ments and severe neutropenia at baseline), candidate for treatment
with HMAs, primary antibacterial (ciprofloxacin or levofloxacin)
and mold-active antifungal (oral posaconazole or voriconazole)
prophylaxis could be advisable during the initial 2–3 cycles of
treatment, with the aim of preventing an infectious complication
and the consequent interruption of HMA treatment.
• Secondary antibacterial, antifungal and anti-herpetic prophylaxis in
patients with previous severe infections could be advisable.
• MDS patients with chronic HBV infection (HBsAg-positive or HBV
DNA-positive), regardless of the disease risk, should always be
considered at high risk of HBV reactivation and should be treated
with tenofovir or entecavir, under the supervision of an infectious
disease or hepatology expert.
• Low-risk MDS patients with resolved HBV infection (HBsAg-nega-
tive and HBV DNA-negative but anti-HBc-positive) receiving only
supportive care and erythropoietin treatment should be managed
according to guidelines for immunocompetent persons [61].
• MDS patients with resolved HBV infection receiving treatment with
lenalidomide or HMA may be considered at low risk of HBV re-
activation, and antiviral treatment is not recommended, but mon-
itoring of seroreversion and/or viremic rebound (defined as de-
termination of HBV DNA, serum HBsAg levels and alanine
transaminase every 3 months), and the subsequent introduction of
pre-emptive therapy are suggested.
• Anti-HBV prophylaxis should be initiated before or concomitantly
with treatment start and should be continued for the duration of
treatment. MDS treatment should not be delayed in subjects with
chronic or active HBV infection.
• Close monitoring of liver function tests and HCV RNA is re-
commended in HCV-infected patients receiving HMAs. Antiviral
treatment should be considered for HCV RNA positive patients and
hepatic disease, according to the specific indication, as soon as
possible under the supervision of an infectious disease or hepatology
expert.
• The use of G-CSF in neutropenic patients is not recommended as
primary infection prophylaxis, although its short-term use may be
considered in neutropenic patients with active or recurrent infec-
tions.
5.2. Does iron chelation play a role in the prevention of infections in MDS
patients?
5.2.1. Preliminary considerations
IO due to chronic red cell transfusions and, to a lesser extent, to
increased gut absorption of iron as a consequence of ineffective ery-
thropoiesis, is a hallmark of MDS [62]. It has been suggested that,
among other damage, IO may also increase the risk of infections in
patients with MDS: [4] (i) through a direct effect of non-transferrin-
bound, free iron (i.e., labile plasma iron) on pathogens, which have an
impaired ability to acquire iron essential for their growth (which would
instead be facilitated in hosts with excess iron loads); (ii) by affecting
the natural resistance to infections, that could be reduced by excess
labile plasma iron through complex mechanisms, including inhibition
of cytokine production and nitric oxide formation, as well as by im-
pairment of macrophage, neutrophil and lymphocyte functions
[63–65].
In the clinical setting, although not yet formally demonstrated by
prospective trials, numerous retrospective studies have reported that
iron chelation therapy (ICT) may improve survival of MDS patients, at
least those with lower-risk disease, probably mainly by repairing/pre-
venting liver and heart toxicity [66,67]. Little attention has been paid,
instead, to the potential benefit of ICT in reducing the risk of infections
[68]. Among the most relevant studies, prevalence of infections during
a 3-year follow-up period (between 2003 and 2005) of US Medicare
beneficiaries was found to be significantly higher in patients with MDS
requiring transfusion support (81%), compared with transfusion-in-
dependent cases (55.7%; P<0.001) [28]. Similarly, Smith et al. ana-
lyzed 4351 MDS patients included between 2007 and 2009 in the
Surveillance, Epidemiology, and End Results (SEER) database. A sig-
nificant increase in incidence of infections per person per year was
found in transfused patients, regardless of treatment [37].
More recently, Lyons et al. reported a 5-year analysis of another US
registry including 599 lower-risk, transfusion-dependent MDS patients.
In this paper, the difference in causes of death between the non-che-
lated and chelated patients was statistically significant (P=0.0014),
and was primarily driven by the higher rates of death due to MDS/AML
and malignancy, but also from infections, in the non-chelated group
[67]. Of interest, severe infections were not reported in a retrospective
analysis of 51 patients with higher IPSS-R risk treated with the oral
chelator deferasirox during the course of their disease, most of whom
received concomitant azacitidine [69].
5.2.2. Recommendations
• IO should be documented at least by ferritin serum levels (> 1000
ng/L) and enumeration of transfusions received (≥20).
• Given the possible multi-targeted effects, ICT should not be denied
to any clinically eligible MDS patients with documented IO, al-
though a possible positive effect on infection rates and severity
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should not be a primary intention for this treatment.
• The use of deferoxamine for this purpose is not recommended, as
this molecule can act as a siderophore, thereby promoting growth of
pathogenic fungi such as Mucor [70]. This is not the case with the
newer oral chelator deferasirox, which is approved in MDS.
5.3. Which vaccinations should be administered to MDS patients?
5.3.1. Preliminary considerations
Although specific epidemiologic data are lacking, MDS patients are
considered at increased risk of contracting, suffering complications, and
dying from seasonal influenza and pneumococcal diseases. Advanced
age and comorbidities, in addition to the hematologic disease-related
immunologic impairment, represent important risk factors for these
infections. In a retrospective cohort study (2006–2010) in three large
and geographically diverse US populations, the rates of pneumococcal
disease in adults with chronic diseases or immunocompromising con-
ditions were compared with rates in healthy adults [71]. Rates of
pneumococcal pneumonia (defined as a pulmonary infection confirmed
by the isolation of Streptococcus pneumoniae from sputum) among per-
sons with diseases of white blood cells aged 50–64 years and≥65 years
were 13.3 and 8.4 times the rates observed in age-matched healthy
controls, respectively. The rates of invasive pneumococcal disease
(confirmed by S. pneumoniae isolation from blood or cerebrospinal fluid
but not sputum) were 15.3 and 13.3 times the rates in age-matched
healthy counterparts, respectively.
The efficacy of vaccinations in immunocompromised patients is
highly variable and the strength of evidence is limited by a small
number of studies and remains an area of clinical uncertainty. Although
several experiences in patients with lymphoproliferative disorders
showed reduced response to certain vaccines, there are no data on the
rates of immunization in MDS patients receiving vaccination against
influenza virus and S. pneumoniae. Considering that immune deficiency
in MDS is mainly related to disorders of the monocytic and myelocytic
lineages immunity and that B cell dysplasia and defect in im-
munoglobulin production is not considered as a major issue in MDS
[72], a satisfactory response to vaccines in MDS patients could be hy-
pothesized. Treatment with recombinant human erythropoietin was
associated with an improved immune response to the influenza vaccine
in hematologic patients, with titers similar to those of healthy subjects
[73]. Influenza and S. pneumoniae vaccinations are safe, and evidence,
although weak, is in favor of vaccinating adults with cancer. For these
reasons, vaccination against influenza virus and S. pneumoniae is re-
commended for immunocompromised hematologic patients, including
those affected by MDS [74,75]. Considering that reduction of exposure
to vaccine-preventable infections is important for risk reduction,
guidelines also recommend influenza vaccination of caregivers,
household members and healthcare contacts to provide a “circle of
protection.”
There is no specific indication in the use of vaccines other than
those against influenza and S.pneumoniae in the MDS population. Adult
MDS patients may receive other vaccines according to the standard
adult immunization schedule [76]. It is important to remember that live
attenuated viral vaccines (i.e. measles, mumps, rubella, varicella and
zoster vaccines) are contraindicated in patients with severe im-
munodeficiency (while adjuvanted varicella-zoster virus subunit vac-
cine is not contraindicated in immunocompromided subjects).
5.3.2. Recommendations
• Vaccination against influenza should be performed annually and is
also recommended for household members.
• Vaccination against S. pneumoniae with 13-valent pneumococcal
conjugate vaccine should be performed at the time of diagnosis of
the hematologic disease regardless of the decision to start treatment,
and in any case before initiating any active therapy. A second
vaccination with 23-valent pneumococcal polysaccharide vaccine
after 2 months may be considered.
6. Conclusions
In this report, a panel of experts in MDS judged whether the body of
evidence was sufficient to provide recommendations regarding infec-
tion control during the course of disease and concluded that there is a
lack of sufficient information with regard to all aspects, starting from
epidemiology. The lack of randomized clinical trials testing screening
and infectious prophylaxis represents uncertainties in the optimization
of infectious disease management thus forcing the panel to use the
methods of consensus for shaping the recommendations of this work. As
a consequence, this document was mainly based on the expertise and
knowledge of experts in the field coordinated by the methods of group
decision and represents the first, albeit weak, consensus report on the
topic.
The development of new drugs, which include targeted therapy and
immunologic modifying agents undergoing investigation, may induce
treatment-related neutropenia and other adverse events which may
result in a change in the risk profile of infections in MDS. The future
treatment landscape of a once mainly untreated disease warrants a
particular sensitization towards infectious epidemiology, screening, risk
assessment and prophylactic approach. Implementation of such in-
formation in registries and clinical trials are highly recommended to
better define guidelines on the assessment and treatment of infections
in MDS patients.
6.1. Practice points
• New treatment strategies for MDS need a parallel progress in the
best approach to prophylaxis and supportive therapy for infections,
particularly in high-risk patients treated with HMAs.
• Infectious risk assessment should be defined before and during ac-
tive treatment of MDS. In particular, baseline severe and prolonged
neutropenia, transfusion-related iron overload, relevant co-morbid-
ities, infectious history and recent hospitalization should be con-
sidered.
• Primary antibacterial, antifungal and antiviral prophylaxis is gen-
erally not recommended, however, in patients at higher risk of in-
fection candidate for treatment with HMAs, primary antibacterial
and mold-active antifungal prophylaxis could be advisable during
the initial 2–3 cycles of treatment, with the aim of preventing an
early infectious complication and the consequent interruption of
HMA treatment.
• Iron chelation therapy in patients with iron overload should be
administered in view also of a possible positive effect on infection
rates and severity
• Vaccination against S.pneumoniae should be administered, possibly
at the time of MDS diagnosis, and vaccination against influenza
should be performed annually to the patients but also to the
household members.
6.2. Research agenda
• Continuous investigation on epidemiology and risk assessment of
infections is required to detect change in the risk profile of infections
in MDS
• Implementation of such information in registries and clinical trials
are highly recommended to better define guidelines on the assess-
ment and treatment of infections in MDS patients.
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